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Objective. To evaluate the use of a Cannabis Sativa oil in the management of 
patients diagnosed with a burning mouth syndrome (BMS). 
Design. Prospective open-label single arm pilot study. 
Setting. University hospital. 
Subjects. Seventeen patients with diagnosed BMS were included. 
Methods. Subjects were treated for 4 weeks with a full cannabis plant extract, 
prepared in specialised pharmacies starting from standardised plant material 
(cannabis flos) by means of Romano-Hazekamp extraction, and diluted in oil 
(1 g of cannabis in 10 g of olive oil). The primary outcome was the change in 
pain intensity (considering Visual Analogue Scale, Present Pain Intensity, 
McGill Pain Questionnaire and Oral Health Impact Profiles) at the end of the 
protocol, and during the succeeding 24 weeks; the neuropathic pain was also 
investigated with a specific interview questionnaire (DN4-interview). Levels of 
anxiety and depression were considered as secondary outcomes, together 
with reported adverse events due to the specified treatment. 
Results. Subjects showed a statistically significant improvement over time in 
terms of a clinical remission of the oral symptoms. Levels of anxiety and 
depression also changed statistically, displaying a favourable improvement. 
No serious reactions were detailed. None of the patients had to stop the 
treatment due to adverse events. 
Conclusions. In this pilot evaluation, the Cannabis Sativa oil provided was 
effective and well tolerated in patients with BMS. Further bigger and properly 
defined randomized controlled trials, with different therapeutic approaches or 
placebo-controlled, are however needed. 
 
 





The International Headache Society has defined the burning mouth syndrome 
(BMS) as “an intraoral burning or dysaesthetic sensation, recurring daily for 
more than 2 hours per day over more than 3 months, without clinically evident 
causative lesions”[1]; the disease has been mostly classified under the header 
“Painful cranial neuropathies”.  
The reported pain is described as moderate to severe, quite comparable to 
tooth ache in intensity, with a distinctive superficial and burning character, 
often accompanied by xerostomia and dysgeusia [2]. In the absence of 
clinically apparent mucosal alterations, the tip of the tongue is most habitually 
affected, but any part of the oral cavity may be involved, more commonly 
occurring in middle-aged and elderly women [3]. Many patients with BMS 
report benefit at night; the pain does not disturb sleep and is better in the 
morning, getting worse during the day [2]. By definition, clinical investigations 
and clinical sensory inspection, without quantitative psychophysical 
measures, should be normal [1]. 
Current evidence, covering neural pathways from the epithelial nerve fibers to 
the brain, indicates that typical BMS, in the majority of cases, is a chronic 
neuropathic pain condition, consisting of 2 main subgroups, peripheral and 
central [4]. 
BMS management should be directed to reduce symptoms and pain, but no 
therapy has been shown to be more effective than others; primary patients’ 
treatment has been based on the avoidance of possible causes of oral 
irritation and the provision of psychological support [5,6]. Recent evidences 
showed that the use of antidepressants (e.g. clonazepam) and alpha-lipoic 
 
 
acid could provide favourable results [7,8]. 
Cannabis (Cannabis sativa, or hemp) and its constituents (in particular the 
cannabinoids) have been the focus of extensive chemical and biological 
research since the discovery of the chemical structure of its major active 
constituent, Δ9-tetrahydrocannabinol (THC) [9]. The plant's behavioural and 
psychotropic properties are attributed primarily to THC, which is produced 
mainly in the leaves and flower buds of the plant; besides it, there are also 
non-psychoactive cannabinoids with several medicinal functions, such as 
cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG), and many 
others [9]. 
In Italy, use of Cannabis sativa for therapeutic purposes (CTP) was first 
authorized in 2006. Suggestions for its use include chronic pain, nausea and 
vomitus associated to chemotherapy, appetite stimulation, hypotension effect 
in glaucoma, and lessening of uncontrolled body and facial movements [10]. 
Magistral formulations of CTP are prepared by extraction from standardized 
products, obtained from dried and minced cannabis inflorescences (containing 
standardized THC and CBD concentration) which that are imported from the 
Dutch Office of Medicinal cannabis [10]: Bedrocan® (mean amounts of 22% 
for THC, and <1% for CBD), Bedrobinol® (13.5% for THC, and <1% for CBD), 
Bediol® (6.3% for THC, and 8% for CBD), and Bedrolite® (0.4% THC, and 9% 
CBD) [11]. 
Introduced in 2007, Bediol® is the brand name for the cultivar Cannabis 
sativa L. ‘Elida’. Cannabis sativa L. ‘Elida’ is one of the first cannabis cultivars 
developed specifically to have a higher CBD content. The effects of CBD are 
distinctly different from THC. Bediol® has a balanced ratio of THC and CBD, 
 
 
and because it is easily tolerated, physicians often prescribe it for patients 
who previously have not used cannabis as a medicine.  
We hypothesized that the use of a full cannabis plant extract, diluted in oil, 
could be useful in reducing oral reported pain not related to a specific clinical 
mucosal alteration. We tested our hypothesis in a prospective, open-label 
study, by giving a galenic preparation of therapeutic Cannabis sativa in a 
cohort of subjects with reported oral burning sensation and/or pain, classified 
as BMS according the International Headache Society criteria. We decided to 
perform this preliminary evaluation to test logistics and gather information 
prior to a larger randomized controlled trial regarding sample size, exclusion 
criteria and materials needed; moreover, considering that Cannabis oil may 
not appeal to all, we also sought to determine its acceptability. 
 
Methods 
   Study population 
The study was approved by the board of CIR-Dental School, University of 
Turin (CIR-PO-2017/01), and was registered on ISRCTN registry (#XXX).  
Caucasian patients attending for the first time the Oral Medicine Section of the 
CIR - Dental School, Turin, Italy, from February 2017 to October 2019, were 
selected for the present study. The same expert oral physician performed the 
baseline conventional intraoral examination (PGA). 
At admission, the following information was recorded: age, gender, education 
level (in years), marital status, job status, social habits, oral reported 
symptoms, systemic disease, and daily medication taken. 
 
 
The inclusion criteria were: a) oral symptoms for at least 12 months; b) age ≥ 
18 years; c) no detectable oral mucosal lesions; d) ability to complete the 
present clinical trial; e) unresponsive to any provided treatment in the previous 
six months, and yet suffering of oral pain. Exclusion criteria were: a) inability 
or unwillingness to provide informed consent; b) noteworthy psychiatric or 
cognitive impairment; c) existence of other diagnoses that could explain the 
neuropathic pain; d) previous diagnosis of Sjögren Syndrome on the basis of 
AECG criteria [12]; e) previously head and neck radiotherapy; f) hepatitis C 
infection; g) pregnant or breast-feeding women; h) patients in treatment with 
psychotropic drugs; i) history of alcohol or substance abuse. 
Patch testing for dental allergens [13] and routine serological analyses were 
required, including quantification of different serum vitamins (B1, B6 and B12), 
folic acid, serum iron (Fe++), serum ferritin, transferrin, fasting blood glucose, 
zinc, and full blood count. 
Different treatment options were discussed, and all patients submitted written 
informed consent. Investigations were performed in full accordance with the 
ethical principles of the World Medical Association Declaration of Helsinki of 
1975, as revised in 2000. 
   Valuation of pain and associated variables 
Different questionnaires were filled in by the same clinician (AG), as 
previously reported [14]. 
The subjective sensation of pain and influence on oral health were assessed 
by Visual Analogue Scale (VAS) [consisting of a 100 mm-vertical line, marked 
wit 0 (=no pain) to 100 (=most severe pain experienced)], McGill Pain 
Questionnaire, Present Pain Intensity (PPI), and by Oral Health Impact Profile 
 
 
questionnaires (OHIP-14, and OHIP-49). The DN4 (Douleur Neuropathique 
en 4 Questions), a screening tool for neuropathic pain consisting of interview 
questions (DN4-interview), was also investigated. 
Levels of anxiety and depression were assessed by Hospital Anxiety and 
Depression Scale (HADS) and Geriatric Depression Scale (GDS). 
   Treatment provided 
Medical cannabis consists of the dried, pulverised and homogenised flowers 
of Cannabis sativa, cultivated under standardised conditions in accordance 
with the requirements of good manufacturing practices [15]. A distinct 
pharmaceutical-grade cannabis preparation was used, obtained from 
Bedrocan International BV (Veendam, The Netherlands) and prepared by 
Proxy Laboratories BV (Leiden, The Netherlands): Bediol®, which contains 
6.3% THC (63 mg/g) and 8% CBD (80 mg/g). The patients obtained the 
medical cannabis by submitting a prescription specifying the THC and CBD 
content. The full cannabis plant extract was prepared in specialised 
pharmacies starting from standardised cannabis plant material (cannabis flos) 
by means of Romano-Hazekamp extraction, and diluted in oil (1 g of cannabis 
in 10 g of olive oil) [16]. Prescription was provided as not-refillable receipt with 
anonymous alpha-numeric code; specifics included exact nomenclature of the 
drug (Bediol®), pharmaceutical form (hereafter oil), dose required (10-40 
drops), and motivation for prescription [10].  
The pharmacy had to provide the patient with a certificate confirming an 
accurate analysis of the final product (in terms of respecting the THC and 
CBD concentrations); this analysis was carried with a liquid chromatography – 
mass spectrometry system, as required by the current Italian legislation.  
 
 
Before starting the protocol, patients were instructed how to take the drug and 
informed about its possible side effects. Dose prescribed ranged from 10 to 
40 drops, as the ideal dosing schedule is currently unknown, since no dose-
finding studies have yet examined the optimal daily amount of specific 
molecular concentrations of THC and CBD [15, 17]. 
The schedule was prescribed as follow: 5 drops twice daily for 5 days, 10 
drops twice daily for 5 days, 15 drops twice daily for 5 days, 20 drops twice 
daily for 13 days. 
Patients were also asked to abstain from using any herbal cannabis or 
cannabinoids other than the oil provided for the entire study duration. 
   Follow-up schedule 
Follow-up visits were conducted at baseline (t1), at the end of the 4-week 
course of treatment (t2), and then 12 (t3) and 24 weeks (t4) after the end of 
treatment. 
   Outcome measures 
The primary outcome of the study was the change in spontaneous pain 
intensity (considering VAS, PPI, McGill Pain Questionnaire and Oral Health 
Impact Profiles) at t2, t3 and t4. 
Levels of anxiety and depression were considered as secondary outcomes, 
as well as reported adverse events due to the THC treatment; the patients 
were provided with a diary to record treatment’s unexpected effects (e.g. 
gastrointestinal disease, headache, dizziness, worsening of dry mouth, or 
anything else reported). 
At every follow-up moment (t1-2-3-4), all the questionnaires were filled in, and 
every adverse effect was recorded. 
 
 
   Statistical analysis 
A descriptive analysis was performed and continuous variables were 
expressed as median and interquartile range (median [IQR]), whereas 
categorical variables as frequencies and percentages. Non-parametrical 
Friedman test was used to assess whether there were any differences among 
the distributions of each score (HADS score, GDS score, MC-GILL Pain, PPI, 
OHIP-14 score, OHIP-49 score, DN4 score and VAS) at four different times 
(t1, t2, t3, t4). Five pairwise comparisons (t2 vs t1, t3 vs t1, t4 vs t1, t3 vs t2 
and t4 vs t2) for each score have been performed using the non-parametrical 
Wilcoxon signed-rank test, standard and adjusted (using the Bonferroni 
multiple testing correction method) p-values were computed. All statistical 
analyses were carried out using R software (version 3.6.2). Statistical 
significance was defined at P value of <0.05. 
 
Results 
Initially 34 patients were selected; 2 of these were not included because 
presenting exclusion criteria (diagnosis of Sjögren Syndrome, and treatment 
with psychotropic drugs). Fifteen patients refused to be part of this study.  
Seventeen patients completed the treatment provided for 4 weeks, of whom 
14 were women (82.4%); the mean age at presentation was 71 years.  
Table 1 reported the sociodemographic characteristics, risk factors and 
haematological evaluation at baseline; only 1 patient (5.9%) showed a 
positive patch test, in particular for nickel, but none dental allergen was 
detected in the oral cavity. 
Table 2 shows the frequency of oral symptoms, their description, and site of 
 
 
involvement; xerostomia and dysgeusia were frequently reported; tongue was 
the most common affected site (more than 70%). 
Table 3 shows the frequency of systemic diseases and the daily medication 
intake in the study group. The most commonly detailed systemic diseases 
were hypertension and hypothyroidism, followed by osteoporosis.  
Subjects were previously treated with different medication for the oral 
symptoms: 5 with clonazepam, 7 with antifungal and nonsteroidal anti-
inflammatory drugs, 2 with salivary substitutes and 3 with systemic steroids. 
   Evaluation of subjective sensation of pain 
Scores distribution at different times is described in Table 4 and Figure 1. 
Over time, all subjects showed a statistically significant improvement in terms 
of a clinical remission of the oral symptoms. The VAS, OHIP-14 and OHIP-49 
scores decreased from baseline (median [IQR] = 8.00 [5.00, 9.00], 27.00 
[14.00, 33.00] and 88.00 [49.00, 108.00], respectively) to the end of the period 
of investigation (median [IQR] = 4.00 [2.00, 5.00], 8.00 [6.00, 12.00], and 
32.00 [20.00, 45.00], respectively). Likewise, the MGP, PPI and DN4 scores 
decreased from the beginning (median [IQR] = 20.00 [13.00, 28.00], 3.00 
[3.00, 4.00] and 3.00 [2.00, 4.00], respectively) to the end of the follow-up 
period (median [IQR] = 3.00 [2.00, 8.00], 1.00 [1.00, 2.00] and 1.00 [1.00, 
2.00], respectively).  
Table 5 shows the distribution of the scores’ differences between the pointed-
out times and corresponding results. The MGP, PPI, OHIP-14, OHIP-49, DN4 
and VAS statistically diminished at t2, t3 and t4 if compared to baseline (both 
unadjusted and Bonferroni-adjusted). However, those improvements showed 
an immediate decrease after 4 weeks of treatment, and remained 
 
 
substantially stable over the next 24 weeks. Comparing data after 12 and 24 
weeks with data after 4 weeks of treatment provided, no statistical 
significances were detected (t3 vs t2 and t4 vs t3) (both unadjusted and 
Bonferroni-adjusted). 
   Analysis of anxiety and depression 
Levels of anxiety and depression changed statistically after treatment 
provided, displaying a favourable lessening (Table 2 and Figure 1). 
The HADS and GDS scores showed a decrease from baseline (median [IQR] 
= 20.00 [8.00, 25.00] and 9.00 [2.00, 11.00], respectively) to the end of the 
period of investigation (median [IQR] = 9.00 [8.00, 15.00] and 3.00 [1.00, 
5.00] respectively). 
When comparing results obtained immediately after the end of therapy (t2) 
with baseline (t1), HADS and GDS score did not show a statistical difference if 
adjusted, whereas HADS alone showed a statistically significant reduction (p 
< 0.05) 24 weeks after end of therapy if compared to baseline (Table 5). 
Similarly, for reported pain, comparing data after 12 and 24 weeks (after the 
end of the therapy) with data after 4 weeks of treatment provided, no 
statistical significances were detected (t3 vs t2 and t4 vs t3) (similarly if 
unadjusted or if Bonferroni-adjusted). 
   Side effects 
No serious reactions were reported with the oil administered. None of the 
patients had to stop the treatment due to adverse events. 
Approximately one-third of the patients experienced adverse events, not 
causing any significant treatment modifications, the most frequent of which 
were dizziness (17.6%), headache (11.8%) and constipation (5.9%). All 
 
 
reported effects were transient and disappeared in 2 weeks after the end of 
the therapy. 




To date, the treatment of BMS remain a challenge and is considered a high 
urgency in oral medicine [18, 19]. Used therapies include hormone 
replacement therapy, anticonvulsants, antidepressants, capsaicin, 
benzodiazepines, analgesics, alpha-lipoic acid, photobiomodulation with laser 
and cognitive therapies; nevertheless, none of them appeared to be superior 
[20]. This wide-ranging diversity should require more detailed studies to 
assess which treatment should be the gold standard for this condition. 
Cannabinoids display their actions due to selective binding to specific 
receptors. Among these, cannabinoids receptors types 1 and 2 (CBR1 and 
CBR2) are the main receptors, being G protein-coupled receptor superfamily 
(GPCR) [21]. CB1 is predominantly expressed in the central nervous system, 
particularly in cerebral cortex, cerebellum, and hippocampus, being activated 
by widespread signalling endocannabinoid system, through endogenous 
cannabinoids, such as anandamide and 2-arachidonyl glycerol [22], where it 
is involved in different pathways of neuronal plasticity, exerting a role of 
neuromodulators, rather than neurotransmitters. Specifically, CBR1 and 
CBR2 receptors are coupled directly to Gi/o proteins to down-regulate of 
adenylyl cyclase activity, which reduces intracellular levels of cyclic adenosine 
monophosphate (cAMP) [21], leading to inhibition of cAMP-dependent protein 
 
 
kinase (PKA) and subsequent reduction of the phosphorylation of Ca2+ and 
K+ channels. Thus, neurotransmitter release, such as glutamate and GABA at 
synaptic level, can be regulated [23] in cortical and medullar pathways of 
locomotion, memory, and pain [24]. However, CBR1 is also expressed in 
gastrointestinal, urogenital, and cardiovascular system, despite its function is 
under scrutiny [25]. CBR2 is also expressed in immune systems, occurring 
also in neurons, glials and endothelial cells of substantia nigra, cerebral cortex 
and hippocampus, with activity and role still undefined when compared to CB1 
[24]. 
Of the components of Cannabis, THC is the most abundant compound, being 
responsible of the most intense psychoactive properties [26]. THC has ability 
to bind to both CBR1 and CBR2, differently from CBD, which is considered an 
isomer of THC deprived of its psychoactive activity, with an overall lower 
affinity than THC for both CBR1 and CBR2, and preference for CBR2 rather 
than CBR1 [27]. THC has been largely known for its psychoactive effects, and 
it is approved treatment for chemotherapy-induced nausea and vomiting, and 
as appetite stimulant amid cachectic patients [26]. On the other hand, CBD 
has been reported to bear analgesic, anti-inflammatory and neuroprotective 
properties, being deployed with encouraging outcomes in the management of 
anxiety, post-traumatic stress disorder [28,29], being approved by FDA as 
antiepileptic for rare disorders [30]. 
The main strength of this study relies on the novelty of the intervention, being, 
to the best of our knowledge, the first study analysing role of cannabinoids in 
management of unresponsive BMS. Our hypothesis derived from previous 
 
 
assessment of the potentialities of THC/CBD formulation in the management 
of other neuropathic disorders [15,31].   
Concerning route of administration, oral and inhaled formulations have been 
approved by Italian Ministry of Health [32], with decoction being the 
preferential pharmaceutical form, whereas inhaler route should be considered 
in those cases where oral form would not be able to provide its therapeutic 
properties. As presented in this work, oil extract form is also allowed. Despite 
inhalation being more often studied in literature and considered as more 
effective [33], for the present pilot study we considered oral drops as being 
more patient-friendly, giving also a better control on the daily dosage among 
the elderly. Furthermore, literature showed that oral formulation could provide 
a lower peak plasma concentration of THC and CBD, as well as a more 
prolonged delay to reach this peak [33] Therefore, it seemed more 
appropriate to use such preparation among BMS patients, who notoriously 
require pain relief over an extended period of time [34]. Furthermore, such 
formulation was preferred to facilitate reproducibility, due to the fact that 
inhaled formulation is not allowed in some countries [26], and that use of 
vaporizers or similar devices could encourage, if not reinforce, the habit of 
smoking in some patients. 
Bediol® formulation, despite the relatively high concentration of THC (6.3%), 
notoriously responsive of psychoactive effects [35], did not lead to serious 
adverse effects in the present study. On the other hand, the well-balanced 
composition of Bediol® in terms of similar concentration of CBD (8%) and THC 
(6.3%) appeared to provide an immediate effect on pain relief, with VAS, PPI, 
MGP, OHIP-14 and OHIP-49 significantly decreased (p < 0.05 in each scale) 
 
 
right after end of treatment (t2)  as well as six months after end of treatment 
(t4), with a sole exception of a minimal increase of OHIP-49 from t3 (average 
29.00) to t4 (average 32.00), still insufficient to jeopardize the scale of 
reduction of OHIP-49 from t4 to t1, where starting average of OHIP-49 was  
88.00. On the other hand, despite what reported in literature with regards to 
the ability for THC/CBD to facilitate management of anxiety and/or depression 
[28,29], Bediol® did not provide any immediate antidepressant nor anxiolytic 
effect, as revealed statistically by p > 0.05 for HADS and GDS at t2 vs HADS 
and GDS at t1 (Table 5). However, a late anxiolytic outcome emerged when 
HADS value at six months after end of treatment were compared to baseline 
values (t4 vs t1 p < 0.05). The latter, might be arguably an indirect 
consequence of the steady reduction of pain experienced by the patients in 
each of the evaluation steps. This association between pain amelioration and 
reduction of anxiety is suggested by the most recent BMS’ etiopathogenetic 
theories, which contemplate an intertwined psychological and neuropathic 
pathway [36]. 
Despite the relatively high concentration of THC, no serious adverse effects 
were experienced. However, this might be a consequence of the smallness of 
the present sample and the relatively brief duration of treatment. Such 
smallness of sample is a consequence of the strict eligibility criteria 
aforementioned. On the other hand, the short-term therapy was decided due 
to the novelty of the product and the absence of empirical evidence in 
literature regarding its application in oral medicine. In this sense, future 
research should compare Bediol® with a different formulation, such as 
Bedrolite®, to assess if similar or even more encouraging results can be 
 
 
obtained with an even lower concentration of THC and a slightly higher 
concentration of CBD. 
To date, no studies can provide a reliable and safe treatment for long-term 
management of BMS both in terms of symptom relief and quality of life [37]. 
Even Clonazepam, considered effective for symptom remission in patients 
with BMS, as showed in a recent meta-analysis [38], bears important 
repercussions, especially in the form of potential addiction in the long-term 
[39,40]. On the other hand, controversy still remains with regards to which 
variables can influence dependence to Cannabis derivates, with some studies 
providing positive correlation with high THC content [41] and other focusing 
on patient-related variables [42]. Moreover, it should be highlighted that 
evidence on these aspects are often provided in samples of young individuals, 
whereas limited data is available on effectiveness and safety of cannabis in 
older subjects, where comorbidity, polypharmacy and increased susceptibility 
to cognitive disorders have to be carefully assessed [26,43]. 
Finally, despite limitations in patients’ enrolment, which might arise due to 
potential impairment caused by THC while driving or at workplace [28], in the 
specific scenario of BMS patients, such restriction is almost marginal, with 
most of BMS patients being diagnosed as elderly women of 60-69 years of 
age, and frequently retired from work [44,45]. In the present work, only 17.8% 
of patients were employed (Table 1) and in no case impairment at workplace 
was experienced. 
With elderly patients being the most commonly affected by BMS, further 
bigger and properly defined randomized controlled trials, with different 
therapeutic approaches or placebo-controlled, are needed in order to 
 
 
ascertain the clinical efficacy of THC products compared with standard 
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Table 1. Sociodemographic characteristics, risk factors and haematological 
evaluation at baseline of 17 analysed patients 
 
Demographical variables  
Age (median [IQR]), years               71.00 [62.00, 72.00] 
Gender = male (%) 3 (17.6)               
Married = yes (%) 14 (82.4) 
Employed = yes (%) 3 (17.6)               
Education level, mean (SD), years 8.9 (5.9) 
Risk factors  
BMI (median [IQ]) 22.31 [21.05, 23.23] 
Smoker = yes (%) 1 (5.9) 
Alcohol consumer = yes (%) 3 (17.6) 
Haematological evaluation  
Vitamin B1, mean (SD), μg/dl 62 (8.6) 
Vitamin B6, mean (SD), μg/l 26.1 (16.3) 
Vitamin B12, mean (SD), pg/ml 393.2 (121.6) 
Folic acid, mean (SD), ng/ml 14 (8.5) 
Serum iron, mean (SD), μg/dl 123.2 (22.9) 
Serum ferritin, mean (SD), μg/l 93.6 (40.8) 
Transferrin, mean (SD), mg/dl 261 (26.6) 
Fasting blood glucose, mean (SD), mg/dl 97.1 (16.5) 





Table 2. Reported oral symptoms, their description, and site of involvement in 
17 BMS patient [frequency and (%)] 
 
Oral symptoms  
Xerostomia 12 (70.6) 
Dysgeusia 9 (52.9) 
Pain or burning every day of the week 17 (100) 
Pain or burning only in the morning 1 (5.9) 
Persistent intensity during the day 9 (52.9) 
Pain or burning during meals 15 (88.2) 
Pain or burning during the night 11 (64.7) 
Sites of involvement  
Tongue 15 (88.2) 
Palate 9 (52.9) 
Lips 5 (29.4) 
Buccal mucosa 3 (17.6) 
Gingiva 5 (29.4) 




Table 3. Incidence of systemic diseases and daily medication consumption in 
17 BMS patients [frequency and (%)] 
  
Systemic disease   
None 2 (11.8) 
Hypertension 5 (29.4) 
Hypercholesterolemia 3 (17.8) 
Osteoporosis 4 (23.5) 
Hypothyroidism 5 (29.4) 
Type II diabetes mellitus 2 (11.8) 
Rheumatoid arthritis 3 (17.8) 
Gastro-Esophageal Reflux Disease 2 (11.8) 
Neurological 1 (5.9) 
Medication consumption  
None 4 (23.5) 
Antiplatelets 2 (11.8) 
Beta-adrenergic receptor blockers 2 (11.8) 
Calcium antagonists 2 (11.8) 
Metformin  1 (5.9) 
L-thyroxin 3 (17.8) 
Proton pump inhibitors 3 (17.8) 
Statins 2 (11.8) 
Vitamin D 3 (17.8) 
 
 
Table 4. Score distribution (median [IQR]) at 4 different time points* and 
corresponding results from the Friedman test 
 
SCORE§ t1 t2 t3 t4 p-value  
HADS 
20.00  
[8.00, 25.00]    
14.00  
[9.00, 17.00]    
9.00  
[7.00, 16.00]     
9.00  
[8.00, 15.00]     0.003 
GDS 
9.00  
[2.00, 11.00]     
4.00  
[1.00, 8.00]      
3.00  
[1.00, 5.00]      
3.00  
[1.00, 5.00]      0.029 
MGP 
20.00  
[13.00, 28.00]   
7.00 [2.00, 
11.00]     
3.00 
 [3.00, 8.00]      
3.00  
[2.00, 8.00]      <0.001 
PPI 
3.00  
[3.00, 4.00]      
1.00  
[1.00, 2.00]      
1.00  
[1.00, 2.00]      
1.00  
[1.00, 2.00]      <0.001 
OHIP-14 
27.00 
[14.00, 33.00]   
8.00  
[4.00, 15.00]     
8.00 
[6.00, 13.00]     
8.00  
[6.00, 12.00]     <0.001 
OHIP-49 
88.00  
[49.00, 108.00]  
34.00  
[20.00, 
49.00]   
29.00  
[22.00, 
43.00]   
32.00 
[20.00, 45.00]   <0.001 
DN4 
3.00  
[2.00, 4.00]      
1.00  
[1.00, 2.00]      
1.00  
[1.00, 1.00]      
1.00  
[1.00, 2.00]      <0.001 
VAS 
8.00  
[5.00, 9.00]      
4.00  
[3.00, 7.00]      
4.00 
[2.00, 5.00]      
4.00  
[2.00, 5.00]      <0.001 
 
 
*t1=baseline; t2= after the end of therapy; t3=12 weeks after t2; t4=24 weeks after t2. 
§SCORES. Visual Analogue Scale (VAS), McGill Pain Questionnaire (MGP), Present Pain 
Intensity (PPI), Oral Health Impact Profile questionnaires (OHIP-14, and OHIP-49), Douleur 
Neuropathique en 4 Questions (DN4), Hospital Anxiety and Depression Scale (HADS), 





Table 5. Distributions of the scores'§ differences between the pointed-out 
times* (median [IQR]) and corresponding results from the Wilcoxon signed-
rank test (both unadjusted and Bonferroni-adjusted) (p-value in bold are 
statistically significant) 
*t1=baseline; t2=after the end of therapy; t3=12 weeks after t2; t4=24 weeks after t2. 
§SCORES. Visual Analogue Scale (VAS), McGill Pain Questionnaire (MGP), Present Pain 
Intensity (PPI), Oral Health Impact Profile questionnaires (OHIP-14, and OHIP-49), Douleur 
Neuropathique en 4 Questions (DN4), Hospital Anxiety and Depression Scale (HADS), 
Geriatric Depression Scale (GDS). 
 
SCORE§    t2 vs t1 t3 vs t1 t4 vs t1 t3 vs t2 t4 vs t3 
HADS    
difference  
(median [IQR])  
-5.00  
[-11.00. -1.00]    
-8.00  
[-14.00. -1.00]    
-9.00  
[-13.00. 0.00]     
-1.00  
[-7.00. 0.00]      
0.00  
[0.00. 0.00]        
p-value  0.015 0.006 0.006 0.064 0.796 
p-value adj. 0.077 0.030 0.031 0.322 1.000 
GDS     
difference  
(median [IQR])  
-1.00  
[-3.00. 0.00]      
-2.00  
[-5.00. -1.00]     
-1.00  
[-5.00. 0.00]      
0.00  
[-1.00. 1.00]       
0.00  
[0.00. 1.00]        
p-value  0.031 0.004 0.027 0.526 0.188 
p-value adj. 0.155 0.019 0.136 1.000 0.942 
MGP  
difference  
(median [IQR])  
-13.00  
[-20.00. -2.00]   
-17.00  
[-21.00. -5.00]   
-18.00  
[-21.00. -5.00]   
0.00  
[-5.00. 1.00]       
0.00  
[-1.00. 0.00]       
p-value  0.002 0.001 0.001 0.219 0.958 
p-value adj. 0.010 0.003 0.004 1.000 1.000 
PPI 
difference  
(median [IQR])  
-2.00  
[-3.00. -1.00]     
-2.00 
[-3.00. -1.00]     
-2.00  
[-3.00. -1.00]     
0.00  
[-1.00. 0.00]       
0.00 
[0.00. 0.00]        
pvalue  0.003 0.000 0.000 0.222 1.000 
p-value adj. 0.016 0.002 0.002 1.000 1.000 
OHIP-14 
Difference 
 (median [IQR])  
-10.00  
[-24.00. -9.00]   
-14.00  
[-26.00. -9.00]   
-15.00  
[-26.00. -12.00]  
0.00 
[-3.00. 1.00]       
0.00 
 [-1.00. 1.00]       
pvalue  0.000 0.000 0.000 0.730 0.245 
p-value adj. 0.002 0.002 0.002 1.000 1.000 
OHIP-49 
Difference 
 (median [IQR])  
-31.00 
[-61.00. -12.00]  
-34.00  
[-71.00. -17.00]  
-38.00  
[-71.00. -18.00]  
-3.00  
[-22.00. 6.00]     
0.00 
[-1.00. 4.00]       
pvalue  0.001 0.000 0.000 0.227 0.528 
p-value adj. 0.003 0.002 0.002 1.000 1.000 
DN4     
difference  
(median [IQR])  
-2.00  
[-2.00. -1.00]     
-2.00  
[-3.00. -1.00]     
-2.00  
[-3.00. -1.00]     
0.00  
[-1.00. 0.00]       
0.00  
[0.00. 0.00]        
pvalue  0.001 0.001 0.004 0.429 0.371 
p-value adj. 0.005 0.005 0.022 1.000 1.000 
VAS     
difference  
(median [IQR])  
-3.00  
[-5.00. -1.00]     
-4.00  
[-5.00. -2.00]     
-4.00  
[-5.00. -2.00]     
0.00 
[-2.00. 1.00]       
0.00  
[0.00. 0.00]        
pvalue  0.003 0.000 0.000 0.166 0.766 




Figure 1. Box plot of each score’s§ distribution at the different times* (black 




*t1=baseline; t2=4 after the end of therapy; t3=12 weeks after t2; t4=24 weeks after t2. 
§SCORES. Visual Analogue Scale (VAS), McGill Pain Questionnaire, Present Pain Intensity 
(PPI), Oral Health Impact Profile questionnaires (OHIP-14, and OHIP-49), Douleur 
Neuropathique en 4 Questions (DN4), Hospital Anxiety and Depression Scale (HADS), 
Geriatric Depression Scale (GDS). 
 
